Charles River Laboratories (CRL) is Reiterated by Barclays to Underweight, Raises Price Target to $ 65

Charles River Laboratories (CRL) was Reiterated by Barclays to “Underweight” according to the research note released today. The brokerage firm has raised the Price Target to $ 65 from a previous price target of $60 . Barclays advised their investors in a research report released on May 20, 2016.

Many Wall Street Analysts have commented on Charles River Laboratories. Gabelli & Co Initiated Charles River Laboratories on Apr 26, 2016 to “Buy”, Price Target of the shares are set at $96.

On the company’s financial health, Charles River Laboratories reported $0.98 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.90. The company had revenue of $354.90 million for the quarter, compared to analysts expectations of $354.81 million. The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS.

Charles River Laboratories closed down -0.23 points or -0.27% at $83.69 with 2,22,736 shares getting traded on Thursday. Post opening the session at $83.62, the shares hit an intraday low of $82.81 and an intraday high of $84.35 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

In a different news, on May 16, 2016, Richard F Wallman (director) sold 1,970 shares at $82.34 per share price. According to the SEC, on May 10, 2016, George Massaro (director) sold 985 shares at $82.04 per share price. On Apr 8, 2016, Davide Molho (Corporate Executive VP) sold 30,667 shares at $80.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Charles River Laboratories International Inc. is a full service early stage contract research company. The Company offers research models for the research and development of new drugs devices and therapies. It develops a portfolio of discovery and safety assessment services both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS) which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA) which provides services that enables the clients to outsource their drug discovery research critical regulatory-required safety assessment testing and related drug discovery and development activities and Manufacturing Support (Manufacturing) which is involved in the production and release of products manufactured by the clients.

Charles River Laboratories

Leave a Reply

Charles River Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Charles River Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.